Advertisement

Anti-Proliferative and Anti-Tumor Effect of α-Interferon in Renal Cell Carcinoma: Correlation with the Expression of a Kidney Associated Differentiation Glycoprotein

  • N. H. Bander
  • G. Gastl
  • D. M. Nanus
  • L. M. Pfeffer
  • C. L. Finstad
  • A. P. Albino
Conference paper

Abstract

Approximately 20000 cases of renal cell carcinoma (RCC) are diagnosed annually in the US. About 25% of these patients have overt metastatic disease at the time of presentation. The median duration of survival in these patients have been reported to be approximately 10 months. Among the rest of the patients with cancers apparently localized to the kidney, the sole effective therapy is surgical excision of the cancer, typically by a radical nephrectomy. About one third of these patients with apparently localized disease (i.e., 25% of the total) will later manifest metastatic disease and ultimately succumb to the cancer. The annual mortality rate for renal cancer in the US is approximately 10 000.

Keywords

Renal Cell Carcinoma Renal Cancer Advanced Renal Cell Carcinoma Renal Cell Carcinoma Cell Line Gp160 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abrams JS, Rayner AA, Wiernik PH, et al. (1990) High-dose recombinant interleukin-2 alone: A regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 82: 1202–1206PubMedCrossRefGoogle Scholar
  2. 2.
    Fossa SD, De Garis ST, Heier MS, et al. (1986) Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma. Cancer 57: 1700–1704PubMedCrossRefGoogle Scholar
  3. 3.
    Krown SE (1987) Interferon treatment of renal cell carcinoma — Current status and future prospects. Cancer 59: 647–651PubMedCrossRefGoogle Scholar
  4. 4.
    Nanus DM, Pfeffer LM, Bander NH, et al. (1990) Antiproliferative and antitumor effects of -Interferon in renal cell carcinomas: Correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer Res 50: 4190–4194PubMedGoogle Scholar
  5. 5.
    Neidhart JA (1986) Interferon therapy for the treatment of renal cancer. Cancer 57: 1696–1699PubMedCrossRefGoogle Scholar
  6. 6.
    Parkinson DR, Fisher RI, Rayner AA, et al. (1990) Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: Phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol 8: 1630–1636PubMedGoogle Scholar
  7. 7.
    Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889PubMedCrossRefGoogle Scholar
  8. 8.
    Sarna G, Figlin R, de Kernion J (1987) Interferon in renal cell carcinoma — The UCLA experience. Cancer 59: 610–612PubMedCrossRefGoogle Scholar
  9. 9.
    Thiebaut F, Tsuruo T, Hamada H, et al. (1987) Proc Natl Acad Sci USA 84: 7735–7738PubMedCrossRefGoogle Scholar
  10. 10.
    Wang JCL, Walle A, Novogrodsky A, et al. (1989) A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogenactivated autologous leukocytes and continuous infusion interleukin-2. J Clin Oncol 7: 1885–1891PubMedGoogle Scholar
  11. 11.
    Umeda T, Niijima T (1986) Phase II study of alpha interferon on renal cell carcinoma — Summary of three collaborative trials. Cancer 58: 1231–1235PubMedCrossRefGoogle Scholar
  12. 12.
    Yagoda A, Bander NH (1989) Failure of cytotoxic chemotherapy, 19831988, and the emerging role of monoclonal antibodies for renal cancer. Urol Int 44: 338–345PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • N. H. Bander
    • 1
    • 2
  • G. Gastl
    • 1
    • 2
  • D. M. Nanus
    • 3
    • 4
  • L. M. Pfeffer
    • 5
  • C. L. Finstad
    • 2
  • A. P. Albino
    • 3
  1. 1.Division of UrologyNew York Hospital-Cornell Medical CenterNew YorkUSA
  2. 2.Laboratory of Human Cancer ImmunologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  3. 3.Laboratory of Mammalian Cell TransformationMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  4. 4.Division of Solid Tumor OncologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  5. 5.Rockefeller University HospitalNew YorkUSA

Personalised recommendations